Cassava Sciences Announces Q4 2025 Earnings on Tuesday

Got story updates? Submit your updates here. ›

Cassava Sciences (NASDAQ:SAVA), a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's disease, is scheduled to announce its Q4 2025 financial results on Tuesday, March 3rd. Analysts expect the company to report a loss of $0.30 per share for the quarter.

Why it matters

Cassava Sciences' lead drug candidate, simufilam, is designed to address underlying mechanisms of neurodegeneration in Alzheimer's patients. The company's quarterly earnings report will provide updates on the progress and development of this potential treatment, which is closely watched by investors and the broader Alzheimer's research community.

The details

Cassava Sciences, headquartered in Austin, Texas, was originally founded as Pain Therapeutics in 1998 before rebranding to its current name in 2017. The company's research program focuses on small molecules that aim to restore normal function to the scaffolding protein filamin A, which has been linked to impaired neuronal signaling and inflammation in Alzheimer's patients.

• Cassava Sciences is expected to announce its Q4 2025 earnings on Tuesday, March 3rd, 2026.
• The company's Q4 2025 earnings call is scheduled for Tuesday, March 10, 2026 at 10:30 AM ET.

What’s next

Investors will be closely watching Cassava Sciences' Q4 2025 earnings report for updates on the progress and development of the company's lead drug candidate, simufilam, as well as any guidance on future milestones.